AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32200610 — intervention group
Group type: EXPERIMENTAL
Intervention: CFNB with continuous infusion of ropivacaine (Group II)
Number of subjects: 90
Study 32200610 — intervention group
Group type: COMPARATOR
Intervention: Basal morphine infusion without CFNB (Group I)
Number of subjects: 90
Study 34158317 — intervention group
Group type: EXPERIMENTAL
Intervention: R2-GDP treatment (rituximab, gemcitabine, dexamethasone, and cisplatin)
Number of subjects: 0
Study 34158317 — intervention group
Group type: EXPERIMENTAL
Intervention: R2-GDP treatment
Number of subjects: 0
Study 34158317 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study 33002429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 1396
Study 33002429 — intervention group
Group type: COMPARATOR
Intervention: Salvage radiotherapy
Number of subjects: 1396
Study 33621983 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 120
Study 33621983 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐BiPAP
Number of subjects: 120
Study 33621983 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 120
Study 33373678 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (200 mg caffeine at breakfast and 100 mg caffeine after lunch)
Number of subjects: 26
Study 33373678 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 26
Study 35418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (n = 23)
Number of subjects: 47
Study 35418281 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n = 24)
Number of subjects: 47
Study 32301668 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with 808 nm wavelength, 50 mW power, continuous mode emission, 4 J/cm2 dosimetry, administered daily for 10 consecutive days
Number of subjects: 14
Study 32301668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 14
Study 36284342 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + 60 °C (carbohydrate-protein-containing drink at 60 °C)
Number of subjects: 12
Study 36284342 — intervention group
Group type: COMPARATOR
Intervention: EX + 4 °C (carbohydrate-protein-containing drink at 4 °C)
Number of subjects: 12
Study 33598741 — intervention group
Group type: COMPARATOR
Intervention: High‐to‐low (Webster's triangle preservation) osteotomy (control group, n = 23)
Number of subjects: 46
Study 33598741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐to‐low osteotomy (study group, n = 23)
Number of subjects: 46
Study 32384495 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved method of finding recurrent laryngeal nerve (lateral approach)
Number of subjects: 158
Study 32384495 — intervention group
Group type: COMPARATOR
Intervention: Control method of finding recurrent laryngeal nerve (blunt separation)
Number of subjects: 158
Study 35064992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with ketamine and rocuronium
Number of subjects: 290
Study 35064992 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo) with ketamine and rocuronium
Number of subjects: 290
Study 33504039 — intervention group
Group type: EXPERIMENTAL
Intervention: PRPA diagnosis
Number of subjects: 5779
Study 35351048 — intervention group
Group type: EXPERIMENTAL
Intervention: Iconic therapy (IT)
Number of subjects: 40
Study 35351048 — intervention group
Group type: COMPARATOR
Intervention: Psychological supportive intervention (SI)
Number of subjects: 40
Study 33813246 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Atlanta Protocol (Group I)
Number of subjects: 100
Study 33813246 — intervention group
Group type: COMPARATOR
Intervention: Paper-based Joint British Diabetes Societies For Inpatient Care Protocol (Group II)
Number of subjects: 100
Study 35577391 — intervention group
Group type: EXPERIMENTAL
Intervention: Scent dogs trained to detect COVID-19 using skin swabs
Number of subjects: 420
Study 33773631 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐lactam treatment (oral amoxicillin 1 g plus clavulanate 125 mg three times a day for 5 extra days)
Number of subjects: 310
Study 33773631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo for 5 extra days)
Number of subjects: 310
Study 33773631 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐lactam treatment
Number of subjects: 310
Study 33773631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 36063595 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict in evidence
Number of subjects: 1027
Study 36063595 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict between two expert sources
Number of subjects: 1027
Study 36063595 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict within the same expert source
Number of subjects: 1027
Study 36063595 — intervention group
Group type: COMPARATOR
Intervention: No conflict control
Number of subjects: 1027
Study 32777193 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (2 mg/kg/day) alone
Number of subjects: 0
Study 32777193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (2 mg/kg/day) plus budesonide nebulization (0.5 mg every 12 h)
Number of subjects: 0
Study 35105318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 1545
Study 35105318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 1545
Study 32093137 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐F Betafood®
Number of subjects: 50
Study 32093137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32093137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A‐F Betafood® and Placebo)
Number of subjects: 50
Study 34791074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (3 gr once daily for 10 days)
Number of subjects: 97
Study 34791074 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (0.5 gr twice daily for 10 days)
Number of subjects: 97
Study 34791074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 97
Study 34791074 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 97
Study 32070923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 0
Study 32070923 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, fluorouracil, and docetaxel (TPF)
Number of subjects: 0
Study 35193470 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 95
Study 35193470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MIR)
Number of subjects: 95
Study 33165148 — intervention group
Group type: EXPERIMENTAL
Intervention: Food
Number of subjects: 295
Study 33165148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothing
Number of subjects: 295
Study 33165148 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care
Number of subjects: 295
Study 33165148 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilities
Number of subjects: 295
Study 33165148 — intervention group
Group type: EXPERIMENTAL
Intervention: Debts
Number of subjects: 295
Study 33165148 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing
Number of subjects: 295
Study 35902297 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 65 mg/m2 plus pazopanib 600–800 mg daily
Number of subjects: 116
Study 35902297 — intervention group
Group type: COMPARATOR
Intervention: Standard weekly paclitaxel 80 mg/m2
Number of subjects: 116
Study 35902297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Paclitaxel plus pazopanib)
Number of subjects: 116
Study 32923171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide
Number of subjects: 121
Study 32923171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 35462214 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar vibration therapy at 80Hz and conventional physical therapy (CPT) for 4 weeks
Number of subjects: 30
Study 35462214 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) for 4 weeks
Number of subjects: 30
Study 35462214 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar vibration therapy at 80Hz and CPT for 4 weeks
Number of subjects: 30
Study 33368766 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR mapping guided ablation (PVI plus STAR mapping)
Number of subjects: 130
Study 33368766 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation (PVI plus CFAE/linear ablation)
Number of subjects: 130
Study 33368766 — intervention group
Group type: COMPARATOR
Intervention: PVI alone ablation
Number of subjects: 130
Study 35079813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, screening-triggered early specialized palliative care intervention programme (questionnaire-based screening and advanced-level nurse counselling)
Number of subjects: 50
Study 35079813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, screening-triggered early specialized palliative care intervention programme
Number of subjects: 50
Study 32873750 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 100
Study 32873750 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 100
Study 34402133 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-OT program plus treatment as usual
Number of subjects: 16
Study 34402133 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 16
Study 35642747 — intervention group
Group type: EXPERIMENTAL
Intervention: VDZ/PTX
Number of subjects: 30
Study 35642747 — intervention group
Group type: COMPARATOR
Intervention: VDZ
Number of subjects: 30
Study 32978424 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed
Number of subjects: 91
Study 32978424 — intervention group
Group type: COMPARATOR
Intervention: Formula A
Number of subjects: 91
Study 32978424 — intervention group
Group type: COMPARATOR
Intervention: Formula B
Number of subjects: 91
Study 37950162 — intervention group
Group type: COMPARATOR
Intervention: Diphereline 11.25 mg
Number of subjects: 133
Study 37950162 — intervention group
Group type: EXPERIMENTAL
Intervention: Microrelin 11.25 mg
Number of subjects: 133
Study 37950162 — intervention group
Group type: EXPERIMENTAL
Intervention: Microrelin 3.75 mg
Number of subjects: 133
Study 34361118 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Structure‐Activity Relationship (QSAR) model
Number of subjects: 1121
Study 34361118 — intervention group
Group type: EXPERIMENTAL
Intervention: QSAR analysis
Number of subjects: 1121
Study 34361118 — intervention group
Group type: EXPERIMENTAL
Intervention: QSAR model validation
Number of subjects: 1121
Study 34361118 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of crystal structures
Number of subjects: 1121
Study 34361118 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of pharmacophoric features
Number of subjects: 1121
Study 32686240 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of structured Respecting Choices interviews
Number of subjects: 30
Study 32686240 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations initiated by providers about living well
Number of subjects: 30
Study 35713906 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored PCP outreach
Number of subjects: 8287
Study 35713906 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PCP outreach
Number of subjects: 8287
Study 35713906 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8287
Study 34549648 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 30
Study 34549648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-chi
Number of subjects: 30
Study 34549648 — intervention group
Group type: COMPARATOR
Intervention: Self-management control
Number of subjects: 30
Study 32613714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT; scaling and root planing plus azithromycin 500 mg every day for 3 days)
Number of subjects: 63
Study 32613714 — intervention group
Group type: COMPARATOR
Intervention: Minimal periodontal treatment (MPT; supragingival professional mechanical plaque removal plus a placebo)
Number of subjects: 63
Study 32613714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT)
Number of subjects: 63
Study 35578568 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmon Pro Full (8 Hz)
Number of subjects: 306
Study 35578568 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmon Pro Full (5‐11‐19 Hz)
Number of subjects: 306
Study 35578568 — intervention group
Group type: EXPERIMENTAL
Intervention: tremoflo C‐100 (5–37 Hz)
Number of subjects: 306
Study 35578568 — intervention group
Group type: EXPERIMENTAL
Intervention: tremoflo C‐100 (7–41 Hz)
Number of subjects: 306
Study 35578568 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-specific reference equations derived
Number of subjects: 306
Study 35578568 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing height
Number of subjects: 306
Study 33714745 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0
Study 33714745 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study 32544852 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD)
Number of subjects: 20
Study 32544852 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD) with adjunctive prebiotic, probiotic, or synbiotic
Number of subjects: 20
Study 34034256 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS2 dietary supplementation for 4 weeks
Number of subjects: 62
Study 34034256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AREDS2 supplementation)
Number of subjects: 62
Study 34511165 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child painting and creative crafting therapy in addition to applied behavior analytic intervention
Number of subjects: 56
Study 34511165 — intervention group
Group type: COMPARATOR
Intervention: Applied behavior analytic intervention (Control)
Number of subjects: 56
Study 36244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) supplementation (0.6 μg/kg)
Number of subjects: 96
Study 36244667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DEX supplementation)
Number of subjects: 96
Study 32942327 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose plus pacifier
Number of subjects: 32
Study 32942327 — intervention group
Group type: COMPARATOR
Intervention: Pacifier
Number of subjects: 32
Study 32297407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 17
Study 32297407 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 17
Study 35941763 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on NSSI
Number of subjects: 23
Study 34415933 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (mART) containing tenofovir/emtricitabine plus lopinavir/ritonavir
Number of subjects: 2444
Study 34415933 — intervention group
Group type: COMPARATOR
Intervention: Infant Nevirapine prophylaxis (iNVP)
Number of subjects: 2444
Study 34415933 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (mART)
Number of subjects: 2444
Study 34323337 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum extract (ActivAMP®)
Number of subjects: 117
Study 34323337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 33989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in single-gender nonmajor biology groups
Number of subjects: 440
Study 33989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in mixed-gender groups for major and nonmajor sections
Number of subjects: 440
Study 33989311 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecture-based Learning (TL)
Number of subjects: 440
Study 33989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in single-gender groups
Number of subjects: 440
Study 33989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in mixed-gender groups
Number of subjects: 440
Study 33989311 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL)
Number of subjects: 440
Study 32501596 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention including four face-to-face sessions with a school nurse over 5 weeks
Number of subjects: 98
Study 32501596 — intervention group
Group type: COMPARATOR
Intervention: Standard school healthcare (control group)
Number of subjects: 98
Study 32501596 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention
Number of subjects: 98
Study 35428822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 1561
Study 32800511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 881
Study 32800511 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 881
Study 35416909 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily fixed-dose triple combination pill (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) therapy
Number of subjects: 700
Study 35416909 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 35416909 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily fixed-dose triple combination pill
Number of subjects: 700
Study 34259405 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment by stages, once every other day, 3 times a week for 3 menstrual cycles.
Number of subjects: 66
Study 34259405 — intervention group
Group type: COMPARATOR
Intervention: Femoston (estradiol tablets/estradiol and dydrogesterone tablets, 1 tablet per day) for 3 menstrual cycles.
Number of subjects: 66
Study 33964254 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary lung resection before systemic treatment
Number of subjects: 51
Study 33964254 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary lung resection after systemic treatment
Number of subjects: 51
Study 33964254 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-organ metastasis
Number of subjects: 51
Study 33964254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsolitary metastasis
Number of subjects: 51
Study 33964254 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 33879218 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (80 mg based on body surface)
Number of subjects: 0
Study 33879218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34339111 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (70% VO2 max to expend 400 kcal)
Number of subjects: 12
Study 35485238 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography with Integrated Pulmonary Index enabled
Number of subjects: 400
Study 35485238 — intervention group
Group type: COMPARATOR
Intervention: Capnography alone
Number of subjects: 400
Study 33892677 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (4 sessions of 60 minutes each)
Number of subjects: 102
Study 33892677 — intervention group
Group type: COMPARATOR
Intervention: Control (no counseling)
Number of subjects: 102
Study 33165218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (audio recording)
Number of subjects: 50
Study 33165218 — intervention group
Group type: COMPARATOR
Intervention: Active control (heart rate monitor)
Number of subjects: 50
Study 33256379 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP plus lenalidomide (R2CHOP)
Number of subjects: 82
Study 35166150 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (90 units injected in 18 sites over cranial sutures)
Number of subjects: 19
Study 34450216 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-TG distance
Number of subjects: 48
Study 34450216 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-TG distance/TW
Number of subjects: 48
Study 34450216 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-TG distance/TDI
Number of subjects: 48
Study 36154752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 (12-session intervention program + glucometer and accessories)
Number of subjects: 0
Study 36154752 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 0
Study 34982021 — intervention group
Group type: COMPARATOR
Intervention: 1TRS (one resistance training session involving eight sets of 10 reps at 70% of 1RM at the bench press)
Number of subjects: 24
Study 34982021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2TRS (two resistance training sessions with a recovery time of 4 hr, same total volume as 1TRS)
Number of subjects: 24
Study 33852651 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) at 1-3 days after ERCP (OG)
Number of subjects: 103
Study 33852651 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) at 4-7 days after ERCP (CG)
Number of subjects: 103
Study 32500636 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenzocimab (1000 mg) given as a 6-hour infusion
Number of subjects: 0
Study 32500636 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenzocimab (1000 mg)
Number of subjects: 0
Study 32500636 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenzocimab
Number of subjects: 0
Study 36163070 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 17
Study 36163070 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 17
Study 33875372 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) combined with cognitive training
Number of subjects: 59
Study 33875372 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (5 Hz) combined with cognitive training
Number of subjects: 59
Study 33875372 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with cognitive training
Number of subjects: 59
Study 33792409 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying sleep position
Number of subjects: 30